Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The future for the treatment of genotype 4 chronic hepatitis C

The future for the treatment of genotype 4 chronic hepatitis C Abstract Hepatitis C virus genotype 4 (HCV‐4) is the most common type of hepatitis C virus (HCV) in the Middle East and Africa, in particular Egypt. Since the development of new protease inhibitors, the response of HCV‐4 to the standard regimen of treatment (pegylated interferon/ribavirin) lags behind other genotypes and has become the most resistant type to treat. The development of therapeutic strategies for all patients with HCV‐4 whether they are naïve, have experienced a virological breakthrough, are relapsers or non‐responders is still a considerable challenge. New types of interferon (Consensus Interferon, Y‐shaped, Albinterferon…) and new direct action antiviral drugs (Nitazoxanide, Vit.D, other) may improve the treatment of patients with HCV‐4. The IL28B CC polymorphism may be associated with sustained virological response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Liver International Wiley

The future for the treatment of genotype 4 chronic hepatitis C

Loading next page...
 
/lp/wiley/the-future-for-the-treatment-of-genotype-4-chronic-hepatitis-c-YBm6hkhE93

References (43)

Publisher
Wiley
Copyright
© 2011 John Wiley & Sons A/S
ISSN
1478-3223
eISSN
1478-3231
DOI
10.1111/j.1478-3231.2011.02704.x
pmid
22212586
Publisher site
See Article on Publisher Site

Abstract

Abstract Hepatitis C virus genotype 4 (HCV‐4) is the most common type of hepatitis C virus (HCV) in the Middle East and Africa, in particular Egypt. Since the development of new protease inhibitors, the response of HCV‐4 to the standard regimen of treatment (pegylated interferon/ribavirin) lags behind other genotypes and has become the most resistant type to treat. The development of therapeutic strategies for all patients with HCV‐4 whether they are naïve, have experienced a virological breakthrough, are relapsers or non‐responders is still a considerable challenge. New types of interferon (Consensus Interferon, Y‐shaped, Albinterferon…) and new direct action antiviral drugs (Nitazoxanide, Vit.D, other) may improve the treatment of patients with HCV‐4. The IL28B CC polymorphism may be associated with sustained virological response.

Journal

Liver InternationalWiley

Published: Feb 1, 2012

There are no references for this article.